Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields) in Combination with PD-1 Inhibitors or Docetaxel, for Second Line Treatment of Non-Small Cell Lung Cancer (EF-24)
Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields) in Combination with PD-1 Inhibitors or Docetaxel, for Second Line Treatment of Non-Small Cell Lung Cancer (EF-24)
Trial Category:
Lung
Phase
III
Contact(s)
Location(s)
Nebraska Cancer Specialists, Omaha, NE
